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Abstract
Background: Ventricular assist devices (VAD) are valuable options for patients with heart failure awaiting cardiac
transplantation. We assessed the impact of pre-transplant VAD implantation on the incidence of post-transplant
infections in a nationwide cohort of heart transplant recipients.
Methods: Heart transplant recipients included in the Swiss Transplant Cohort Study between May 2008 and December
2012 were analyzed. Cumulative incidence curves were used to calculate the incidence of bacterial or Candida
infections (primary endpoint) and of other infections (secondary endpoint) after transplant. Cox regression models
treating death as a competing risk were used to identify risk factors for the development of infection after transplant.
Results: Overall, 119 patients were included in the study, 35 with a VAD and 84 without VAD. Cumulative incidences
of post-transplant bacterial or Candida infections were 37.7 % in VAD patients and 40.4 % in non-VAD patients. In
multivariate analysis, the use of cotrimoxazole prophylaxis was the only variable associated with bacterial/Candida
infections after transplant (HR 0.29 [95 % CI 0.15-0.57], p < 0.001), but presence of a VAD was not (HR 0.94, [95 % CI
0.38-2.32], p = 0.89, for continuous-flow devices, and HR 0.45 [0.15 – 1.34], p = 0.15, for other devices). Risk for
post-transplant viral and all fungal infections was not increased in patients with VAD. One-year survival was
82.9 % (29/35) in the VAD group and 82.1 % (69/84) in the non-VAD group. All 6 patients in the VAD group
that died after transplant had a history of pre-transplant VAD infection.
Conclusion: In this nationwide cohort of heart transplant recipients, the presence of VAD at the time of transplant
had no influence on the development of post-transplant infections.
Keywords: Outcome, Cardiac transplantation, Mechanical heart support
Background
Ventricular assist devices (VAD) are an established op-
tion for patients suffering from end-stage heart failure
that may not survive until a suitable donor comes [1]. A
major complication associated with VAD support is the
high incidence of infections of the devices, ranging from
25-70 % [2–4], which can be life-threatening and/or may
jeopardize subsequent transplantation [5]. Some series
show that Staphylococcus spp. and Candida spp. are the
most important microorganisms involved in VAD infec-
tions [6, 7]. Any part of the device can be involved in
these infections, including the driveline, the cannulae,
the pocket or the pump itself [8, 9].
Large registries of patients have shown that mortality
after heart transplantation is not increased in patients
with VAD support, particularly when continuous-flow
left ventricular devices are used [10, 11]. However, data
on the impact of VAD implantation on the incidence of
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post-transplant infections are conflicting, in particular
when the device is infected at the time of transplantation.
While some studies reported that pre-transplant VAD-
related infections correlated with a higher incidence of
bacteremia following transplantation and a decreased
survival [12, 13], in another study the presence of VAD
increased the risk for local, but not for disseminated
infections, and VAD infections were not associated
with inferior outcomes [14]. Additionally, despite some
reports suggesting that VAD may generate a relative
state of immunosuppression after implantation [15, 16],
there is a lack of current data reporting on the incidence
of opportunistic viral or fungal infection in heart trans-
plant recipients with pre-transplant VAD.
The Swiss Transplant Cohort Study (STCS) is a compre-
hensive prospective nationwide cohort including the
majority of solid-organ transplantations (SOT) performed
in Switzerland. We conducted an observational study of
all heart transplant recipients included in the STCS to
evaluate the impact of the implantation of a VAD on the
incidence of post-transplant infections.
Methods
Patient population and study design
The STCS is a multicenter nationwide cohort study in-
cluding more than 95 % of all solid-organ transplant re-
cipients in Switzerland from May 2008 onward [17].
Three adult and pediatric heart transplant programs
participate in the STCS: Bern, Lausanne-Geneva, and
Zurich; these centers also perform most of the VAD
implantations in Switzerland. For the present study, we
included consecutive patients transplanted from May
2008 to December 2012 with at least one follow-up and
written informed consent for participation in the STCS.
Data on demographic parameters, transplant type, co-
morbidities, immunosuppressive treatment, antimicrobial
drugs, rejection, infectious and non-infectious events
are collected at enrollment, at six months and every
12 months on standardized data forms. We used the STCS
database for available data regarding the occurrence of
infections, demographic and clinical data, as well as
long-term graft function and survival. A specific ques-
tionnaire was used by the investigators to collect de-
tailed pre-transplant data that were not included in the
STCS database. Specifically, data such as the type of
VAD (continuous-flow vs. others), date of implantation
and duration of VAD support, INTERMACS (Interagency
Registry for Mechanically Assisted Circulatory Support)
score [18], incidence and cause of any pre-transplant
infections (and whether the infection was considered as
being currently active or cured), antibiotics used and
their duration, blood transfusions, laboratory values
(creatinine) and body mass index (BMI) were studied.
All cases of death occurring after transplantation were
reviewed by a clinician in charge of patients and a
STCS investigator.
Immunosuppressive and antimicrobial prophylaxis after
transplantation
Immunosuppressive regimens varied among centers, but
in general, all patients received, after an intraoperative
methylprednisolone bolus, induction therapy (with either
antithymocyte globulins [ATG] or basiliximab), followed
by triple maintenance therapy with calcineurin inhibitors
or mTOR inhibitors, an antimetabolite (mycophenolate
or azathioprine) and steroids. Cotrimoxazole was ad-
ministered for prevention of Pneumocystis jiroveci
pneumonia and toxoplasmosis for a duration varying
from 6 months to lifelong. Antifungal prophylaxis was
not standardized and depended on specific individual
risk factors. Prevention of cytomegalovirus (CMV) disease
consisted in antiviral prophylaxis with valganciclovir for
high-risk patients (donor positive/recipient negative for
CMV). For CMV seropositive recipients, two programs
administered antiviral prophylaxis and one program
managed the patients by preemptive therapy [19].
Clinical definitions
The definitions of infections in (heart) transplant recipi-
ents follow the guidelines of the Infectious Diseases Study
Group of the STCS and are in concordance with the
American Society of Transplantation recommendations
for screening, monitoring and reporting of infectious
complications in immunosuppression trials in recipients
of organ transplantation [20]. Briefly, each episode of in-
fection was reviewed by the local transplant infectious
diseases specialist and classified in proven, probable, and
possible infection according to standardized criteria.
Asymptomatic episodes were classified as colonization
(bacteria, fungus) or asymptomatic replication (virus)
depending on the pathogen. Only proven/probable infec-
tions were included in the present analysis, except for
CMV, for which all infections were included.
The definitions of infection in pre-transplant patients
with VAD follow the guidelines from the International
Society for Heart and Lung Transplantation [21]. VAD-
specific infections are those related to the device hard-
ware, which do not occur in non-VAD patients (e.g. pump,
cannulae, percutaneous driveline, and pocket infections).
VAD-related infections refer to infections that may also
occur in patients who do not have VADs (e.g. infective
endocarditis, bloodstream infections, mediastinitis). Ac-
cording to these definitions, an episode of infection may
be defined as being both a VAD-specific and a VAD-re-
lated infection (e.g. in case of a bloodstream infection sec-
ondary to a pump pocket infection). Finally, non-VAD
infections were defined as those not affected by the pres-
ence of the VAD, such as lower respiratory tract infection,
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cholecystitis, Clostridium difficile infection or urinary tract
infection. Acute rejection was defined according to the
original International Society for Heart and Lung
Transplantation (ISHLT) Heart Biopsy Grading Scale [22].
Statistical analysis
Descriptive analysis was used to determine the baseline
and clinical characteristic of the subjects in the study.
Univariate analysis was performed using partial tests of
fitted univariable logistic regression models for cate-
gorical variables and continuous variables. Cumulative
incidence curves were calculated by presence of VAD to
estimate the probability of first bacterial or Candida in-
fection after transplantation treating death prior to an
infection as competing risk; Kaplan-Meier curves were
calculated to estimate patient survival for patients with
and without VAD. We chose, as a primary endpoint,
only bacterial or Candida infection, because they are the
most common infections developing after VAD implan-
tation. We analyzed the incidence of other infections
(viral, all fungal) as secondary endpoints.
Variables that might influence the development of in-
fection after transplantation based on previous literature,
such as implantation of VAD device, type of the VAD
(continuous-flow vs. other), age, gender, prior diabetes,
transplant center, donor age, donor sex, cotrimoxazole
prophylaxis and type of immunosuppressive therapy were
analyzed with a Cox proportional hazards regression
model, taking into account death as a competing risk
by using non-parametric multiple imputation techniques
to recover the missing potential censoring information
for individuals who died [23–25]. In the multivariable
analyses, all covariates with missing information were
imputed by the most frequent class (categorical covar-
iates) or by the median of the available values (con-
tinuous covariates). A p-value of less than 0.05 was
considered significant. All analyses were performed
with R version 2.15.1 [26].
Results
Study population
Overall 119 patients (35 with a VAD and 84 without VAD)
underwent heart transplantation between May 2008 and
December 2012, and informed consent and at least one
follow-up were available in all patients. Baseline characte-
ristics are shown in Table 1. There were no significant dif-
ferences between the two groups. Mean follow-up after
transplantation was 1.36 years for the whole cohort. Im-
munosuppressive regimens were similar between groups.
Pre-transplant characteristics of patients with VAD
Table 2 shows the characteristics of patients with VAD
at the time of implantation according to the presence or
not of a pre-transplant infection. The majority of the
Table 1 Baseline characteristics of heart transplant recipients
included in the study
No VAD (n = 84) VAD (n = 35)
Follow-up, years; mean (SD) 1.38 (1.07) 1.31 (1.06)
Recipient age, years; mean (SD) 47.9 (16.9) 45.7 (16.7)
Recipient gender, male; n (%) 62 (73.8) 28 (80)
Donor age, years; mean (SD) 41.3 (16.5) 40.7 (15.0)
Donor gender, male; n (%) 48 (57.1) 24 (68.6)
Prior diabetes; n (%) 15 (17.9) 4 (11.4)
BMI, kg/m2; mean (SD) 24.4 (4.7) 25.2 (4.8)
Serum creatinine, umol/l; mean (SD) 125.9 (66.0) 103.3 (47.1)
Underlying disease; n (%)
- Cardiomyopathy
- Ischemic
- Congenital heart disease
- Other
41 (48.8)
23 (27.4)
5 (5.9)
15 (17.9)
18 (51.4)
12 (34.3)
1 (2.9)
4 (11.4)
Cold ischemia, min; mean (SD) 151 (54.3) 164 (54.4)
Bypass time, min; mean (SD) 168 (65.6) 186 (71.1)
Induction therapy; n (%)
- Basiliximab
- ATG
- None
7 (8.3)
71 (84.5)
6 (7.1)
6 (17.1)
24 (68.6)
5 (14.3)
Maintenance at discharge; n (%)
- Tacrolimus
- Cyclosporin
- MMF/MPA
- Azathioprine
- Everolimus
- Steroids
28 (33.3)
39 (46.4)
63 (75.0)
21 (25.0)
9 (10.7)
74 (88.1)
10 (28.6)
13 (37.1)
22 (62.9)
7 (20.0)
3 (8.6)
27 (77.1)
There were no significant differences between the two groups. VAD
ventricular-assist device, BMI body mass index, ATG anti-thymocyte globulin,
MMF mycophenolate mofetil, MPA mycophenolic acid
Table 2 Pretransplant characteristics at the time of VAD
implantation according to pre-transplant VAD infection
Characteristics VAD infection
n = 18
No VAD infection
n = 17
Age, years; mean (SD) 52.3 (9.7) 39.1 (20)
Gender, male; n (%) 15 (83.3) 14 (82.4)
BMI, kg/m2; mean (SD) 28.4 (6.1) 22.9 (6)
Median time from VAD implantation
to transplantation, days; median (IQR)
293.5
(121–593)
101
(37.5-206)
INTERMACS score; median (IQR) 1.5 (1–4) 2 (1–3)
Creatinine, μmol/l; mean (SD) 105.3 (58.6) 90.9 (35.6)
Type of VAD; n (%)
- Heartmate® II
- Berlin Heart® EXCOR
- Heartware®
- Thoratec®
- Levitronics®
9 (37.1)
6 (34.3)
1 (14.3)
2 (11.4)
0 (0.0)
5 (29.4)
6 (35.3)
4 (23.5)
1 (5.8)
1 (5.8)
Active infection at the time
of transplant
10/18 (55.5) -
VAD ventricular-assist device, BMI body mass index, INTERMACS interagency
registry for mechanically assisted circulatory support
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patients received a Heartmate®-II (40 %) or a Berlin Heart®
EXCOR (34.3 %). The median INTERMACS score at
the time of implantation was 2 (IQR 1–4). Median
time from VAD implantation to transplantation was
161 days (IQR 75–354).
The incidence of infections from implantation to heart
transplantation is shown in Table 3. Eighteen patients
(51.4 %) developed 43 episodes of VAD-specific or re-
lated infections, with a median of one episode per pa-
tient (IQR 0–1). On note, three patients developed 11,
five and four episodes of infection, respectively. Overall,
24/43 (55.8 %) episodes were classified as being VAD-
specific infections and 32/43 (74.4 %) were VAD-related
infections, so that 13/43 (30.2 %) were classified as being
both VAD-specific and VAD-related infection (Fig. 1).
Additionally, 29 episodes of non-VAD infection were re-
ported (data not shown). Eight out of the 18 patients
with VAD-specific or related infections were considered
by the clinician in charge as being free from the VAD
infection before transplantation, and they were not re-
ceiving antibiotic therapy at the time of transplantation
(Additional file 1: Table S1).
Impact of VAD implantation on post-transplant outcomes
Cumulative incidences of first episode of bacterial or
Candida infection at one year were 37.7 % in VAD
patients and 40.4 % in non-VAD patients (Fig. 2). The
most common sites of post-transplant infections were
the respiratory tract in patients without VAD (25.7 %
of post-transplant infections) and the surgical site in
patients with VAD (38.9 %) (Table 4). Other post-transplant
outcomes were similar between patients with or without
VAD. After one year of follow-up, patient survival was
82.9 % (29/35) in the VAD group and 82.1 % (69/84) in
the non-VAD group.
In multivariate analysis, cotrimoxazole prophylaxis (HR
0.29, [95 % CI [0.15-0.57], p < 0.001) was the only variable
associated with bacterial or Candida infections, but
VAD was not (HR 0.94, [95 % CI 0.38-2.32], p = 0.89,
for continuous-flow devices, and HR 0.45 [0.15 – 1.34],
p = 0.15, for other devices) (Table 5). We did not ob-
serve any influence of VAD on the incidence of all fun-
gal infections (HR 0.27 [95 % CI 0.06-1.30], p = 0.10) or
viral infections (HR 0.91, [95 % CI 0.32-2.56], p = 0.86,
for continuous-flow devices, and HR 0.64 [0.18 – 2.22],
p = 0.48, for other devices) (Table 5).
Impact of pre-transplant VAD infection on post-transplant
outcomes
Additional file 1: Table S1 shows the clinical characteris-
tics of the 18 patients with pre-transplant VAD-specific
or related infection. Six of them developed 10 post-
transplant infections. Out of these 10 infections, four
episodes were surgical site infections, three primary bac-
teremias and three respiratory tract infections. Additional
file 1: Table S1 also shows the 6 reported post-transplant
deaths in VAD group. All of them occurred in patients
Table 3 Type of pre-transplant infection in patient with a VAD
Infections VAD patients n = 18
Total number of VAD-specific or related infectionsa n = 43
VAD-specific infections; n (%)
• Proteus mirabilis
• Enterobacter spp.
• Staphylococcus aureus
• MSSA
• MRSA
• Coagulase-negative Staphylococci
• Escherichia coli
• ESBL
• Serratia marcescens
• Enterococcus faecalis
• VRE
• Other
24 (55.8)
6 (13.9)
4 (9.3)
3 (7.0)
2 (4.7)
1 (2.3)
3 (7.0)
3 (7.0)
0 (0)
2 (4.7)
2 (4.7)
0 (0)
8 (18.6)
VAD-related infections; n (%)
• Staphylococccus aureus
• MSSA
• MRSA
• Coagulase-negative Staphylococci
• Enterobacter spp.
• Proteus mirabilis
• Escherichia coli
• ESBL
• Enterococcus spp.
• VRE
• Candida spp.
• Other
32 (74.4)
7 (16.3)
2 (4.7)
5 (11.6)
3 (7.0)
7 (16.3)
5 (11.6)
3 (7.0)
0 (0)
3 (7.0)
0 (0)
1 (2.3)
4 (9.3)
ESBL extended spectrum betalactamase, MSSA methicillin susceptible
Staphylococcus aureus, MRSA methicillin resistant Staphylococcus aureus,
VAD ventricular-assist device, VRE vancomycin-resistant Enterococci
aIn 13 cases, infection was classified as being both VAD-specific and
VAD-related, therefore the addition of numbers is >100 %
Fig. 1 Number of episodes of pre transplant infection in patients
with VAD according to the ISHLT classification
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who had a pre-transplant VAD-specific or related infec-
tion (patients #2, #4, #10, #14, #17, #18). Therefore, death
during the first year post transplant occurred in 6/18
patients (33.3 %) with pre-transplant specific or related
VAD infection and in 0/17 (0 %) in patients without
pre-transplant VAD infection. Mean age was 59 years
(SD 8.57) in patients who died as compared to 51 years
(SD 7.08) in those who survived. There were no signifi-
cant differences in the induction and maintenance im-
munosuppressive regimen in these two groups. In 3 of
these 6 patients the infection was considered to be cured
and in 3 patients the infection was considered to be active.
Accordingly, 3 out of the 6 patients were receiving anti-
biotic therapy at the time of transplant against the patho-
gen responsible for the VAD infection. Five of these 6
patients died within the first week after transplantation. In
one of these 6 cases, infection was considered the direct
cause of death (patient #3, multiorgan failure). The patient
was bacteremic with Proteus spp and Klebsiella spp that
were also found on culture performed from the pus at the
VAD site. Effective antibiotics were given at the time of
transplant, but the clinical situation was complicated
by a colic ischemia and a multi-organ failure followed
by death. The other 5 patients died of non-infectious
causes (1 hemodynamic failure, 2 graft dysfunctions,
and 2 post surgical hemorrhages).
Discussion
In this nationwide cohort of heart transplant recipients,
we assessed the impact of the pre-transplant implantation
of VAD on the incidence of post-transplant infections. We
were interested in investigating whether patients who
underwent transplantation with a VAD had a higher inci-
dence of post-transplant infections, specifically in patients
with a VAD infection before transplantation. We found
that VAD was not a risk factor for developing bacterial or
Candida infection (the main endpoint of the study), or
other post-transplant infections. Indeed, the main variable
associated with a higher incidence of post-transplant Can-
dida or bacterial infection was the lack of cotrimoxazole
prophylaxis. However, in the group of patients with VAD,
we observed that those with a previous VAD-specific or –
related infection had impaired post-transplant survival.
Post-transplant mortality in patients with VAD support
has been assessed in several studies, including a large
registry from the ISHLT with more than 100,000 heart
transplant recipients [11]. In this study, 1-year mortality
of patients with continuous-flow left VAD at the time of
transplantation was 87 %, as compared to 88 % in pa-
tients without left VAD with inotropic support and 90 %
in patients without left VAD and without inotropic sup-
port. Of note, survival was significantly lower in patients
with biventricular VAD (81 % at one year). This is in
concordance with the results of our study, as we showed
that patients with a VAD in place had similar rate of
graft and patient survival. However, other studies have
concluded that short-term survival is diminished in
patients with a pre transplant VAD [27, 28].
Less data are available regarding the incidence of post-
transplant infection in patients with a VAD in place at
Fig. 2 Cumulative incidence of bacterial or candida infection after transplantation according to whether the patient had a VAD or not at the time
of transplantation
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the time of transplantation. Some studies have described
a relative immunosuppressive state in patients with
VAD, showing a higher incidence of hypogammaglobuli-
nemia [15] and a decrease in the response of lymphocyte
stimulation tests [16] after VAD implantation. Thus it
can be hypothesized that these patients might potentially
develop more opportunistic infections after transplan-
tation. In our analysis, VAD was not associated with a
higher incidence of infection, including bacterial, fungal
and viral infections. In line with the results of our study,
two additional studies revealed that having a VAD did
not increase the risk of post-transplant infections [29,
30]. Indeed, in the study of Drakos et al. [30], patients
with a VAD had fewer post-transplant infections than
the group transplanted without VAD. This could be
related to a cautious administration of immunosuppres-
sion at the time of transplant in patients with VAD. In
that regard, we found a trend towards a lower frequency
of administration of lymphocyte-depleting antibodies in
patients with VAD, although in our analysis the type of
induction therapy was not associated with a higher rate
of infectious complications. It seems clear that im-
munosuppressive regimens need to be individualized in
patients with VAD support, avoiding induction therapy
with depleting antibodies particularly in those patients
with pretransplant VAD infection.
Because a significant proportion of patients with a
VAD could have developed a VAD infection before
transplantation, there is some concern that this infection
would persist after removal of the device, resulting in
post-transplant surgical site infections, mediastinitis,
bacteremias and sepsis. In a study involving 149 patients
with VAD, 69 % of patients with a pre-transplant driveline
infection developed significantly more post-transplant
surgical site infections and had a longer length of stay than
patients without infection, although post transplant sur-
vival was not affected by the presence of a pre transplant
infection [14]. In our study only one patient developed a
surgical site infection after transplantation with the same
microorganism that was responsible for a pre-transplant
VAD infection, without disseminated infection. However,
in the VAD group, all six patients that died after transplant
had a pre-transplant VAD infection. Obviously, patients
who had early mortality were not anymore at risk for
developing post-transplant infections, so that we try to
reduce the bias by applying a competing risk analysis to
take death into consideration for the incidence of post
transplant infection. Although the cause of death in
these patients was only attributed to infection in one
case, it is plausible that infection might have actually
contributed to mortality. This higher mortality in patients
with pre-transplant VAD infection is concordant with
other recent studies reporting that infection of VAD had
deleterious consequences on allograft and patient survival
[13, 31]. Despite that, VAD infection remains an indication
for heart transplantation, which it is the only curative
treatment in this scenario.
We observed a low rate of specific or related VAD infec-
tions caused by antibiotic-resistant pathogens. Of note, we
observed that a minority of patients had methicillin-
resistant Staphylococcus aureus (MRSA) infection [32],
with no cases of vancomycin-resistant enterococci (VRE)
and extended-spectrum beta lactamases (ESBL)-producing
Enterobacteriaceae infections. This is in keeping with the
current epidemiology of infection at our country. Al-
though we did not have detailed data of the antibiotic
resistance patterns after transplant for our study, other
Table 4 Outcomes after transplantation in patients with VAD
and without VAD
No VAD
(n = 84)
VAD
(n = 35)
Patients with ≥1 post transplant
bacterial/candida infection episode, n (%)
39 (46.4) 12 (34.3)
Number of episodes of bacterial/candida
infections per patient; mean (SD)
0.83 (1.31) 0.51 (0.82)
Number of post-transplant bacterial/candida
infections episodes
70 18
Sites of bacterial/candida infections; n (%)a
- Respiratory tract
- Bacteremia
- Urinary tract
- Surgical site
- Otherb
18 (25.7)
11 (15.7)
12 (17.1)
17 (24.3)
17 (24.3)
4 (22.2)
5 (27.7)
3 (16.7)
7 (38.9)
2 (11.1)
Microorganisms; n (%)
- Escherichia coli
- Coagulase Negative Staphylococci
- Staphylococcus aureus
- Pseudomonas sp.
- Clostridium difficile
- Enterobacter sp.
- Candida sp.
- Polymicrobial
- Other
10 (14.3)
6 (8.6)
6 (8.6)
6 (8.6)
5 (7.1)
6 (8.6)
6 (8.6)
5 (7.1)
19 (27.1)
2 (11.1)
1 (5.6)
1 (5.6)
0
2 (11.1)
2 (11.1)
1 (5.6)
3 (16.7)
7 (38.9)
Viral infections
- CMV infection
- VZV infection
- HSV infection
31 (36.9)
8 (9.5)
15 (17.9)
8 (22.9)
3 (8.6)
1 (2.9)
Other fungal infections
- Aspergillus spp.infection
- Pneumocystis jiroveci pneumonia
7 (8.3)
3 (3.6)
1 (2.9)
0 (0.0)
Length of stay after transplant, days; mean (SD) 60.8 (65.0) 82.9 (127.6)
Patients with treated acute rejection, n (%) 57 (67.9) 22 (62.9)
Survival; n (%) 69 (82.1) 29 (82.9)
There were no significant differences between groups
VAD ventricular-assist device, CMV cytomegalovirus, VZV varicella-zoster virus,
HSV herpes simplex virus
aOne episode of infection could be counted multiple times according to the
number of infectious sites
bOther infections: 8 gastro-intestinal infections, 5 muco-cutaneous infections,
4 bone/joint infections, 2 catheter-related infections
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studies in the transplant population in Switzerland showed
that the incidence of infection caused by resistant path-
ogens was less than 1 % for VRE (2 episodes out of 392
enterococcal events) [33] and 14 % for ESBL-producing
Enterobacteriaceae [van Delden et al., manuscript in
preparation]. So far, no infections due to carbapenemase-
producing bacteria have been recorded in SOT recipients
in Switzerland.
We acknowledge that the present study has several
limitations. First, as compared to other studies based on
a registry, our study has a relatively modest sample size,
so we might have not been able to correct our analysis
for the different confounders, such as the different anti-
microbial and immunosuppressive protocols used at
each transplant center. Also, a significant percentage of
the VAD used in this study were pulsatile-flow devices,
which have a significantly higher risk of becoming in-
fected that the continuous-flow devices, so that different
outcomes might have been observed if these new devices
would have been used (although we did not identify the
use of non-continuous-flow devices as a risk for post
transplant infection). However, we used a comprehen-
sive database with standardized definitions and were
able to describe in detail the epidemiology of infections
after heart transplantation.
Conclusion
In this nationwide cohort of heart transplant recipients,
transplantation with VAD at the time of transplant had
no influence on the development of post-transplant
infections. However, patients with a history of pre-
transplant VAD infection showed a significantly higher
early post-transplant mortality.
Additional file
Additional file 1: Table S1. Clinical characteristics of the 18 patients
with a pre-transplant VAD-specific or related infection. (DOCX 16 kb)
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